Medicaid expansion increased use of adjuvant therapy for NSCLC

Stephen V Liu shared an article by Hamza Rshaidata on X:

“In addition to developing treatments for lung cancer, we need to work on access to these therapies.

Report Clinical Lung Cancer shows Medicaid expansion increased use of adjuvant therapy for NSCLC (70.2% vs 62.3% pre-expansion) and more likely to start quickly.”

Tittle: The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients with Lung Cancer

Authors: Hamza Rshaidata, Shale J. Mackb, Scott H. Koenemanc, Jonathan Martinb, Gregory L. Whitehornb, Isheeta Madekaa, Sarah W. Gordond , and T. Olugbenga T. Okusanya.

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.